1. PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES. (23rd June 2022) Authors: Knoebl, P.; de Haard, H.; Parys, W.; Ulrichts, P.; Rocca, F.; Guglietta, A.; Ayguasanosa, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 2175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗